Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

Multimodal approach reduces missed opportunities for influenza vaccination in RA patients

30 Sep 2018

Multimodal approach reduces missed opportunities for influenza vaccination in RA patients

Using a multimodal intervention may improve uptake of influenza vaccination in patients with rheumatoid arthritis (RA), reports a study, adding that some subgroups may need a more potent approach for equivalent efficacy.

Of the 228 patients with RA who participated in the study (904 preintervention visits), 197 returned for at least one postintervention visit (721 postintervention visits). There was a 47-percent preintervention frequency of any missed opportunities for influenza vaccination, and this decreased to 23 percent postintervention (p<0.001).

The relative hazard among those vaccinated for influenza vaccination post vs preintervention period was 1.24 (p=0.038).

Each of the following was independently associated with missed opportunities preintervention: younger age, less frequent office visits, higher erythrocyte sedimentation rate and negative attitudes about vaccines. These factors no longer correlated with missed opportunities postintervention.

However, the intervention appeared to be not as effective in the following: non-Hispanic black patients, non-English speakers, those residing outside of the New York City metropolitan area and those reporting prior adverse reactions to vaccines.

This study recruited RA patients from a single centre. The authors tracked each rheumatology outpatient visit for missed opportunities for influenza vaccination, defined as a visit in which an unvaccinated patient without contraindications remained unvaccinated or lacked documentation of vaccine recommendation in the electronic medical record (EMR).

Subsequently, providers received a multimodal intervention consisting of an education session, EMR alerts and weekly provider-specific e-mail reminders. The authors compared missed opportunities pre- and postintervention, and analysed the determinants of missed opportunities.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.